Holen Sie sich die Stockscreener-App
29.96
0.64%
0.19
Handel nachbörslich:
30.18
0.22
+0.73%
Schlusskurs vom Vortag:
$29.77
Offen:
$30.01
24-Stunden-Volumen:
1.57M
Relative Volume:
5.41
Marktkapitalisierung:
$843.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-5.3526
EPS:
-5.5973
Netto-Cashflow:
$-73.92M
1W Leistung:
-5.25%
1M Leistung:
-0.30%
6M Leistung:
+17.35%
1J Leistung:
+21.74%
1-Tages-Spanne:
$29.00
$31.59
1-Wochen-Bereich:
$29.00
$34.86
52-Wochen-Spanne:
$16.54
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Vergleichen Sie LENZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
29.96 | 849.10M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
LENZ Therapeutics announces FDA Approval of VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia - Eyes On Eyecare
FDA approves LENZ Therapeutics' VIZZ for presbyopia - Eyes On Eyecare
LENZ Therapeutics' Eye Drop Scores First FDA Approval… - inkl
LENZ Therapeutics gets FDA nod for presbyopia eye drop (LENZ) - Seeking Alpha
Why is LENZ Therapeutics Inc. stock attracting strong analyst attentionPost Market Alerts For Every Investor - jammulinksnews.com
Is it time to cut losses on LENZ Therapeutics Inc.Fast Movement Forecast for Trading Success - Newser
Applying big data sentiment scoring on LENZ Therapeutics Inc.Earnings Report Summary with Market Impact - Newser
LENZ Therapeutics Announces FDA Approval of VIZZ for Treatment of Presbyopia - VisionMonday.com
Has LENZ Therapeutics Inc. found a price floorFree Triple Digit Return Stock Predictions - Newser
Using data models to predict LENZ Therapeutics Inc. stock movementSmart Entry Signals for Active Traders - Newser
Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia - Conexiant
How many analysts rate LENZ Therapeutics Inc. as a “Buy”Wealth Building Trend Scanner For Smart Trading - jammulinksnews.com
Lenz Therapeutics stock rises after FDA approves presbyopia eye drops - Investing.com Australia
Lenz Therapeutics stock rises after FDA approves presbyopia eye drops By Investing.com - Investing.com India
FDA Approval: Revolutionary 10-Hour Eye Drops Promise Freedom from Reading Glasses - Stock Titan
How volatile is LENZ Therapeutics Inc. stock compared to the marketAI Powered Entry Points From AI Tools - jammulinksnews.com
Lenz (LENZ) Q2 Revenue Jumps 604% - The Motley Fool
Lenz Therapeutics Prepares for LNZ100 Launch - TipRanks
Is a relief rally coming for LENZ Therapeutics Inc. holdersFree AI Powered High Return Stock Calls - Newser
FY2025 EPS Estimate for LENZ Therapeutics Lifted by Analyst - Defense World
LENZ Therapeutics gains on NDA submission in China for presbyopia drug LNZ100 - MSN
LENZ Therapeutics shares climb as FDA review of presbyopia treatment stays on schedule - MSN
LENZ Therapeutics shares surge as FDA review of presbyopia drug on track - Investing.com Australia
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss - Yahoo Finance
How Efficient Is LENZ Therapeutics Inc. at Controlling Operating CostsStrong Buy With Technical Confidence Supported - metal.it
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
LENZ Therapeutics and the Imminent FDA Decision for LNZ100: A High-Conviction Biotech Play Ahead of PDUFA - AInvest
LENZ Therapeutics Preps Launch of First Aceclidine Eye Drops: FDA Decision in 9 Days, $195M Global Deals Secured - Stock Titan
What makes LENZ Therapeutics Inc. stock price move sharplyBuy and Hold Return Summary with Charts - Newser
Has LENZ Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewMomentum-Based Prediction for Quick Returns - Newser
Why LENZ Therapeutics Inc. stock attracts strong analyst attentionWeekly Trend Screener with Momentum Picks - Newser
Will LENZ Therapeutics Inc. benefit from macro trendsEquity Portfolio Outlook and Performance Summary - Newser
LENZ Therapeutics: Undervalued Ahead Of PDUFA (NASDAQ:LENZ) - Seeking Alpha
Published on: 2025-07-29 12:30:28 - metal.it
LENZ Therapeutics (NASDAQ:LENZ) Receives Buy Rating from HC Wainwright - Defense World
CORXEL submits NDA for LNZ100 in China for presbyopia treatment - Ophthalmology Times
LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia - The Manila Times
H.C. Wainwright raises LENZ Therapeutics stock price target to $48 ahead of FDA decision - Investing.com India
LENZ's Breakthrough Presbyopia Eye Drop Heads to China FDA with $95M Milestone Potential - Stock Titan
Is a relief rally coming for LENZ Therapeutics Inc. holders Free Oversold Recovery Opportunity Stocks - Newser
What are LENZ Therapeutics Inc. company’s key revenue driversFree Investment Case Studies - jammulinksnews.com
What are the latest earnings results for LENZ Therapeutics Inc.Skyrocketing profit margins - jammulinksnews.com
Is LENZ Therapeutics Inc. a growth stock or a value stockBreakneck growth rates - jammulinksnews.com
How does LENZ Therapeutics Inc. generate profit in a changing economyInvest smarter and grow your wealth faster - jammulinksnews.com
How strong is LENZ Therapeutics Inc. company’s balance sheetTriple-digit wealth increases - jammulinksnews.com
What is the dividend policy of LENZ Therapeutics Inc. stockNavigate market shifts with confidence - jammulinksnews.com
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lenz Therapeutics Inc-Aktie (LENZ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Jun 27 '25 |
Sale |
30.46 |
200,000 |
6,093,000 |
1,767,275 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.25 |
133,924 |
4,051,201 |
1,967,275 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.35 |
100,877 |
3,061,617 |
1,047,912 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 18 '25 |
Sale |
29.95 |
100,000 |
2,995,000 |
1,148,789 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 10 '25 |
Sale |
29.00 |
350,000 |
10,150,000 |
1,248,789 |
| Olsson Shawn | Chief Commercial Officer |
Apr 09 '25 |
Option Exercise |
2.08 |
1,400 |
2,912 |
4,733 |
| Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 07 '25 |
Option Exercise |
1.04 |
4,200 |
4,368 |
49,200 |
| Olsson Shawn | Chief Commercial Officer |
Dec 16 '24 |
Option Exercise |
2.08 |
3,333 |
6,933 |
3,333 |
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):